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Parathyroid hormone and bone histology: Response to hypocalcemia in
osteitis fibrosa. The parathyroid hormone (PTH) response to hypocalce-
mia was studied in 18 hemodialysis patients with osteitis librosa, and
the relationship with PTH and bone histology in 26 hemodialysis
patients. Hypocalcemia was produced during hemodialysis by the use
of a dialysate devoid of calcium. Both amino (N) (P <0.05) and carboxy
(C) (P < 0.005) terminal PTH attained maximum levels by 15 mm
despite only a minimal decline in plasma calcium. Throughout the
remainder of the study, C and N-PTH levels remained elevated but did
not increase despite a further decline in plasma calcium. Five patients
increased both C and N-PTH to maximum or near maximum levels by
the first sampling, although plasma calcium remained above 9 mgldl.
Basal C and N-PTH correlated with the maximum levels of each
induced by hypocalcemia (P < 0.005). Both basal N-PTH and the
maximum change in C-PTH produced by hypocalcemia correlated with
osteoblastic osteoid, active resorption, osteoclasts/mm2, and endosteal
fibrosis (P < 0.005). In conclusion, (1) a minimal decline in plasma
calcium produces a maximum C and N-PTH response; (2) an altered
PTH set point may be present in some hemodialysis patients; (3) the
correlation between basal and maximally stimulated PTH levels sug-
gests that basal PTH levels may reflect parathyroid gland mass; and (4)
a correlation with basal and stimulated PTH and bone histology is
present.
Hormone parathyroidienne et histologie osseuse: Réponse a l'hypocal-
cémie dans l'ostéite fibreuse. La reponse de l'hormone parathyroIdienne
(PTH) a l'hypocalcémie a éte étudiée chez 18 malades hemodialyses
avec une ostélte fibreuse, et Ia relation entre Ia PTH et l'histologie
osseuse chez 26 malades hemodialyses. L'hypocalcémie était produite
pendant l'hémodialyse par l'emploi d'un dialysat depouvu de calcium.
Les PTH amino (N) (P < 0.05) et carboxy (C) (P < 0.005) terminales
atteignaient des niveaux maximum en 15 mm, malgré une diminution
seulement minime du calcium plasmatique. Pendant le reste de l'étude,
les niveaux de C et N-PTH sont restés élevés mais n'ont pas augmenté
malgré une diminution supplémentaire du calcium plasmatique. Cinq
malades ont augmenté C et N-PTH a des niveaux maximaux ou voisins
du maximum lors du premier recueil plasmatique, bien que le calcium
plasmatique soit resté au-dessus de 9 mg/dl. C et N-PTH de base étaient
corrélées avec les niveaux maximum de chacune lors d'une hypocalce-
mie (P < 0.005). N-PTH basale et Ia modification maximale de C-PTH
entramnée par l'hypocalcémie étaient corrélées avec l'ostCoIde ostéo-
blastique, Ia resorption active, les ostéoclastes/mm2, et Ia fibrose endo-
stéale (P < 0.005). En conclusion, (1) une diminution minime de Ia
calcémie entraine tine réponse maximale de C et N-PTH; (2) une
alteration du niveau de regulation de Ia PTH peut Ctre présente chez
certains malades hemodialysés; (3) Ia correlation entre le niveau de
PTH de base et apres stimulation maximale suggère que Ies niveaux de
PTH de base pourraient réfléter Ia masse glandulaire parathyroIdienne;
enfin (4) une correlation entre Ia PTH de base et après stimulation et
l'histologie osseuse est présente.
mone (PTH) [4], and diminished production of renal-derived
vitamin D metabolites [5]. Although decreased renal clearance
of carboxy (C) terminal PTH may contribute to the elevation ol
plasma PTH levels [6], evidence is present to confirm the
existence of a hyperparathyroid state in most patients with
chronic renal failure. Such evidence includes the finding ol
parathyroid gland hyperplasia on surgical or autopsy specimens
[7], and the presence of target-organ changes such as osteitis
fibrosa [81. In addition, in vitro studies with parathyroid glands
have suggested that PTH secretion is altered in secondary
hyperparathyroidism [9].
The secretion of PTH appears to be regulated in a sigmoidal
relationship over a narrow range of plasma calcium [101. Thus,
the maximum and minimum secretion rate of PTH is separated
by only small changes in plasma calcium concentration. Animal
studies have shown that hypocalcemia produces rapid PTH
secretion despite only a minor decrement in plasma calcium [10,
11]. However, with prolonged and more profound hypocalce-
mia, maximum PTH levels are not maintained, although they
remain above basal levels [121. The decrease in PTH levels may
be secondary to the exhaustion of pre-existing hormonal stores
or altered metabolism [133. Conversely, increments of plasma
calcium produce PTH suppression, but total suppressibility is
not observed despite marked hypercalcemia [14]. Studies in
dialysis patients suggest that pre-dialysis PTH levels are re-
duced by the use of a dialysate calcium exceeding 6.0 mg/dl
[15]. In vitro evidence suggests that hyperplastic parathyroid
glandular tissue will suppress PTH secretion in response to an
acute elevation of calcium, although the inhibition occurs at a
higher set point than normal glands [9]. Finally, McCarron et a!
[16] have shown in renal transplant recipients with residual
hyperparathyroidism that the increment in PTH levels pro-
duced by EDTA-induced hypocalcemia correlates with the
mass of the parathyroid glands.
Hemodialysis patients, because of vascular accessibility and
the usual presence of marked parathyroid gland hyperplasia,
provide an unique opportunity to evaluate PTH secretion in
response to hypocalcemia. The magnitude of the induced
hypocalcemia is easily controlled by altering the dialysate
calcium concentration during dialytic therapy. Furthermore,
the majority of these patients have osteitis fibrosa which may
Secondary hyperparathyroidism is a common finding in
chronic renal failure [1]. Its occurrence is attributed to multiple
factors including phosphate retention [21, calcium malabsorp-
tion [3], skeletal resistance to the action of parathyroid hor-
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Table 1. Clinical and biochemical data
Patient no. Age/Sex
Duration
of
dialysis
months
Plasma
Serum
Phosphorus
mg/dl
Alkaline
phosphatase
U/liter
Calcium
mg/dl
C-PTH
ng/ml
N-PTH
ng/ml
Magnesium
mEq/liter
I 61/M 79 10.16 0.73 0.37 2.40 5.7 109
2 59/M 12 9.57 0.96 0.12 2.34 3.6 125
3 381M 24 9.66 1.94 0.12 2.17 11.0 106
4 59/M 4 8.85 1.38 0.72 2.39 10.0 33
5 61/M 62 8.92 2.37 0.93 1.84 8.6 133
6 72/F 7 8.66 1.16 0.36 1.88 4.3 143
7 641M 7 9.50 1.16 0.10 2.24 5.7 177
8 59/M 68 9.94 1.30 0.28 2.27 9.2 155
9 48/M 30 10.64 1.63 0.95 1.71 6.7 147
10 61/M 32 9.57 1.26 0.29 2.21 6.9 134
11 53/M 9 8.98 1.25 0.07 2.30 4.2 10!
12 49/M 72 8.75 1.1! 1.32 2.15 6.8 319
13 48/M 48 10.39 2.36 0.28 1.91 6.3 139
14 61/F 60 9.02 0.96 0.83 2.35 6.0 958
15 26/M 67 9.59 2.32 0.65 1.96 9.2 336
16 52/M 9 8.32 1.00 0.47 2.25 6.4 200
17 47/M 8 9.50 2.16 1.34 NA 4.0 29!
18 60/M 4 8.80 1.99 0.36 NA 3.6 47
Mean value SE 54 2.5 33 7 9.38 0.15 1.50 0.13 0.53 0.09 2.15 0.05 6.6 0.53 203 49
Normal values 8.5—10.5 0.05—0.5 0.05—0.4 1.5—1.9 2.5—4.5 <130
Abbreviation: NA, not available.
provide a measure of the biological activity of PTH. Thus, the
purpose of this study is to evaluate PTH secretion in response
to hypocalcemia and compare PTH levels with bone histology.
Methods
Eighteen maintenance hemodialysis patients with osteitis
fibrosa documented by bone biopsy were studied. In some of
the patients with osteitis fibrosa, mineralization was minimally
decreased, but osteoclastic and osteoblastic activity were pre-
sent. In addition, active bone formation was documented by
tetracycline labeling. These patients could be clearly separated
from patients with "low turnover" osteomalacia and thus were
categorized as osteitis fibrosa. All available osteitis fibrosa
patients were included in the study (Table 1). None of the
patients were receiving vitamin D, its analogs, or oral calcium
supplements. The mean duration of dialysis was 33 7 months.
Each patient was maintained on dialysis three times each week.
The dialysate used during regular dialysis contained either 3.0
or 3.5 mEq/liter of calcium. The protocol was approved by the
Institutional Review Board of The University of Oklahoma
Health Sciences Center and informed consent was obtained
from each patient.
After baseline blood samples were obtained for calcium,
magnesium, phosphate, alkaline phosphatase, and PTH, hemo-
dialysis was initiated with a zero-calcium dialysate. Blood was
drawn from the arterial side of the dialyzer at 15 to 30-mm
intervals for plasma calcium and PTH determinations. Arterial
BP was monitored at 15-mm intervals. Hemodialysis with a
zero calcium dialysate was continued until the plasma calcium
reached 7,0 mg/dl (total duration, 90 to 210 mm) at which time
the dialysate was changed to 3.0 or 3.5 mEq/liter calcium. The
plasma calcium did not fall below 6.5 mg/dl in any patient.
Plasma calcium measurements were performed with an auto-
mated calcium analyzer (Calcette, Precision Systems, Inc.,
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Fig. 1. PTH response to hypocalcemia in patients with osteitisfibrosa.
The mean (± 5EM) amino-terminal (•) PTH and the mean carboxy-
terminal (0) PTH concentration increase to significantly higher levels at
is mm despite only a small decrement in plasma calcium. Further
decrements in plasma calcium do not produce higher levels of amino or
carboxy-terminal PTH. All comparisons are between the mean baseline
concentration and subsequent levels. Symbols are: , P < 0.05, ', P <
0.01.
Fig. 2. In five patients, the plasma calcium
was greater than 9 mg/dl after 30 mm of zero
calcium dialysis, and yet all five patients
responded with marked increases in both C-
PTH (A) and N-PTH (B).
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Fig. 3. Comparison between baseline C-PTH and N-PTH and the maximum concentration of each achieved after a hypocalcemic stimulus. A
Baseline C-PTH and the maximum C-PTH produced by a hypocalcemic stimulus are graphed and show a significant correlation. B Baseline N-
PTH and the maximum N-PTH produced by a hypocalcemic stimulus are graphed and show a significant correlation.
Sudbury, Massachusetts) and plasma magnesium by atomic
absorption spectrophotometry (Model 5000, Perkin-Elmer
Corporation, Norwalk, Connecticut). Serum phosphate and
alkaline phosphatase were measured by standard laboratory
techniques. Plasma immunoreactive PTH was determined by
radioimmunoassay as previously described [17]. Binding char-
acteristics of the antibody for the carboxy-terminal fragment
(C) and the antibody for the amino-terminal fragment (N) have
been reported previously [181. Normal plasma values are 0.05 to
0.50 ng/ml for the carboxy-terminal fragment and 0.05 to 0.40
ng/ml for the amino terminal fragment.
Transiliac bone biopsies were performed with a biopsy needle
(Mayo, Model 8501-577, Zimmer, Greensboro, North Carolina)
which has an internal diameter of 7.5 mm. The undecalcified
specimens were dehydrated, defatted, and then embedded in
methyl methacrylate. Five-micron sections were prepared and
stained by the modified Goldner technique. Sections were
examined quantitatively with a Merz-Schenk reticle (Wild,
Heerbrugg, Switzerland) at a magnification of x200 with a Leitz
Ortholux Microscope (Leitz, Wetzlar, West Germany) [19].
Bone histology categories evaluated were: (1) osteoblastic
osteoid-the fraction of trabecular surface covered by osteo-
blasts; (2) active resorption surface—the fraction of trabecular
surface covered by osteoclast laden resorption lacunae; (3) the
A
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Table 2. Bone histology
Osteoblastic Active bone Endosteal
osteoid % resorption % fibrosis %
trabecular trabecular Osteoclasts/ span giosal
Patient no. surface surface mm2 area
1 4.5 4.5 1.0 0.7
2 5.4 5.4 1.7 0.9
3 4.2 4.2 1.8 0.5
4 4.2 4.2 1.5 0.7
5 8.3 8.3 1.9 2.7
6 8.8 8.8 2.1 1.6
7 7.4 7.4 1.7 2.6
8 5.5 5.5 2.6 2.0
9 9.5 9.5 2.9 4.0
10 9.8 9.8 4.7 2.0
II 5.2 5.2 2.1 1.5
12 14.3 14.3 2.9 4.9
13 12.8 12.8 3.4 5.5
14 12.2 12.2 6.2 17.9
15 19.2 19.2 9.0 6.3
16 12.3 12.3 6.2 7.6
17 33.9 14.6 6.1 7.4
18 9.4 2.8 1.0 2.6
19 0 0 0 0
20 0 1.5 0.1 0
21 0 0 0 0
22 0 0.3 0.1 0
23 0.3 0.9 0.7 0.08
24 0 0 0 0.03
25 0 5.2 2.1 0.2
26 0.7 2.4 0.8 —
Normal values 0.76 0.76 0.15 0.12 0.05 0.04 0
number of osteoclasts per square millimeter of spongiosal bone
(osteoclasts/mm2); and (4) fibrosis area—the fraction of spon-
giosal area occupied by endosteal fibrosis. In addition, the
number of osteoclasts were also expressed as osteoclasts per
trabecular boundary length. The fibrosis area was also calculat-
ed as a percentage of marrow space.
The PTH response to hypocalcemia was analyzed in the 18
hemodialysis patients with osteitis fibrosa. Comparison of the
several histologic categories with PTH responsiveness was
made in 26 patients. These included the 18 patients mentioned
above, plus eight hemodialysis patients with "low turnover"
osteomalacia who had been studied previously [201.
Statistical analysis was performed using the Student's t test
and linear regression analysis. Data are expressed as the mean
value SEM.
Results
As shown in Table 1, the mean baseline plasma calcium was
9.38 0.15 mg/dl. Mean baseline levels of plasma magnesium,
serum phosphate, and serum alkaline phosphatase were 2.15
0.05 mEq/liter, 6.6 0.53 mg/dl, and 203 49 U/liter, respec-
tively. The serum alkaline phosphatase was elevated in 12
patients. While the basal plasma level of C-PTH was elevated in
all 18 patients, basal N-PTH values were elevated in only eight
patients.
At the commencement of hemodialysis, the mean plasma
calcium concentration was within the normal range. During
hemodialysis with a zero calcium dialysate, plasma calcium
levels declined throughout the hemodialysis (Fig. 1). The base-
line plasma calcium represents the mean SE of 18 hemodialy-
sis patients. At 15 and 45 mm, plasma calcium was determined
only in ten patients. By 120 mm, the plasma calcium in three
patients had fallen below 7.0 mg/dl, and therefore the study was
terminated in these patients. After 120 mm, the number of
patients declined because of the removal of patients in whom
the plasma calcium fell below 7.0 mg/dl which accounts for the
failure to observe a further decline in mean plasma calcium after
120 mm. With the decline in plasma calcium, a marked increase
in both C-PTH and N-PTH was observed (Fig. 1). Both C-PTH
and N-PTH increased to maximum levels despite only a mini-
mal decrement in plasma calcium. By 15 mm after the initiation
of hemodialysis, the mean plasma C-PTH level increased from
1.50 0.13 to 2.36 0.25 ng/ml (P < 0.001) and remained
elevated throughout the remainder of the study. Similarly,
mean plasma N-PTH achieved maximum levels by 15 mm. At
15 and 45 mm, plasma PTH was determined in only ten patients.
By 120 mm, the number of patients declined because patients
were removed from the study when the plasma calcium fell
below 7.0 mg/dl. Despite a decline in the number of patients, the
differences between baseline C-PTH and N-PTH remained
significant throughout the entire 210 mm. In addition, once
maximum values were attained by 15 mm, there were no
statistical differences in the mean C-PTH and N-PTH values
throughout the study despite a progressive decrement in plasma
calcium.
At the commencement of the hemodialysis, three patients
had a plasma calcium greater than 10 mg/dl. These patients
responded with marked elevation of both C-PTH and N-PTH by
30 mm despite the fact that the plasma calcium remained greater
than 9.0 mg/dl. Two additional patients, with basal plasma
calcium concentrations between 9 and 10 mg/dl, had marked
increases in C-PTH and N-PTH at 30 mm although the plasma
calcium concentration did not fall below 9 mg/dI. In these five
patients, C-PTH increased from a basal level of 1.44 0.27
ng/ml to 2.13 0.39 ng/ml at 30 mm. N-PTH increased from a
basal level of 0.40 0.14 ng/ml to 1.14 0.28 ng!ml after 30 mm
of zero calcium dialysis. As shown in Figure 2, these changes
represented 77 10% and 74 10% of the maximum levels of
C-PTH and N-PTH, respectively, observed during the study.
The possibility that baseline PTH values may reflect parathy-
roid gland mass was explored by comparing baseline to maxi-
mum levels achieved after the induction of hypocalcemia. As
shown in Figure 3, both basal C-PTH and N-PTH correlated
with the maximum values of C-PTH (P < 0.005) and N-PTH (P
<0.005) produced by the hypocalcemic stimulus.
To ascertain if passage through the dialyzer affected C-PTH
or N-PTH, concentrations of C-PTH and N-PTH were mea-
sured simultaneously in six patients in the arterial line and after
passage through the dialyzer in the venous line. No significant
differences were observed for C-PTH (1.57 0.20 ng/ml arterial
vs. 1.61 0.18 ng/ml venous) or N-PTH (1.17 0.34 ng/ml
arterial vs. 1.27 0.23 nglml venous).
Bone histologic categories are shown in 26 hemodialysis
patients in Table 2, Eighteen patients had osteitis fibrosa and
eight patients "low turnover" osteomalacia. Basal, the maxi-
mum change in response to hypocalcemia (zmax), and the
maximum level (attained during hypocalcemia) of N-PTH and
C-PTH were compared to the histologic categories listed in
Table 2; in addition these PTH parameters were also compared
to osteoclasts per trabecular boundary length and to the endos-
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Table 3. A correlation of basal, the maximum change in N-PTH and C-PTH (maximum), and the maximum level of N-PTH and C-PTH with
histologic parameters
Basal iMaximum Maximum
N-PTH C-PTH N-PTH C-PTH N-PTH C-PTH
Osteoblastic osteoid,
% trabecular surface
r = 0.73
P < 0.005
r = 0.40
P <0.005
r = 0.60
P < 0.005
r = 0.80
P < 0.005
r = 0.71
P < 0.005
r = 0.56
P < 0.005
Active resorption,
% trabecular surface
r = 0.66
P < 0.005
r = 0.31
P < 0.025
r = 0.48
P < 0.005
r = 0.74
P < 0.005
r = 0.55
P < 0.005
r = 0.60
P < 0.005
Osteoclasts/mm2
spongiosal area
r = 0.52
P < 0.005
r = 0.21
NS
r = 0.32
P < 0.025
r = 0.71
P < 0.005
r = 0.42
P < 0.005
r = 0.54
P < 0.005
Osteoclasts/mm2 of trabecular
length
r = 0.66
P < 0.005
r = 0.25
NS
r = 0.45
P < 0.005
r = 0.75
P < 0.005
r = 0.54
P < 0.005
r = 0.52
P < 0.005
Endosteal fibrosis,
% spongiosal area
r = 0.56
P < 0.005
r = 0.08
NS
r = 0.48
P < 0.005
r = 0.65
P < 0.005
r = 0.50
P < 0.005
r = 0.42
P < 0.005
Endosteal fibrosis,
marrow area
r = 0.54
P < 0.005
r = 0.06
NS
r = 0.44
P < 0.005
r = 0.64
P < 0.005
r = 0.45
P < 0.005
r = 0.41
P < 0.005
I
z
5)
a)
a,
a,
teal fibrosis area of marrow space (Table 3). As shown in Table
3, significant correlations were found between basal N-PTH
and osteoblastic osteoid, active resorption, osteoclasts/mm2,
osteoclasts per trabecular boundary length, endosteal fibrosis
per spongiosal area, and endosteal fibrosis per marrow area.
For basal C-PTH, some correlations were observed but were
not as significant as with basal N-PTH. The best correlations
with bone histology were found with zmax C-PTH. There were
correlations with max N-PTH, but they were not as significant
as with max C-PTH. With respect to maximum levels of C-
PTH and N-PTH and the histologic categories, significant
correlations were observed. In general the correlations with
maximum levels of C-PTH and N-PTH and histologic catego-
ries were comparable.
In Figure 4, the correlation of basal N-PTH with osteoblastic
osteoid (r = 0.73, P < 0.005) and active resorption (r 0.66, P
<0.005) is presented. The best correlation with bone histology
and PTH was found with zmax C-PTH. These data are present-
ed in Figure 5. As displayed, significant correlations were found
between max C-PTH and osteoblastic osteoid (r 0.80, P <
0.005), active resorption (r = 0.74, P < 0.005), osteoclasts/mm2(r = 0.71, P < 0.005), and endosteal fibrosis (r = 0.65, P <
0.005).
Discussion
As a result of a hypocalcemic stimulus, all 18 patients with
osteitis fibrosa responded with an increase of both C-PTH and
N-PTH. By the earliest sampling interval all patients had a
marked increase in C-PTH and N-PTH, and the mean value of
both C-PTH and N-PTH represented the maximum value
attained during the dialysis. This maximum response occurred
despite only a minor decrement in plasma calcium. These
findings are compatible with the results of both Mayer and
Hurst [10] and Blum et al [11] who have shown in the normal
A
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Fig. 4. Comparison of baseline N-PTH concentration and bone histology. A significant correlation is observed between baseline N-PTH
concentration and A osteoblastic osteoid (%), and B active bone resorption (%).
20
bovine that below a calcium concentration of 9 mg/dl, a small
decrease in plasma calcium evoked a pronounced increase in
PTH secretion rate, Fox and Heath [12] by inducing a rapid
decrease of plasma calcium (mean decrement, 1.7 0.2 mg/dl)
and then maintaining that level constant for 8 hr, demonstrated
that a fivefold increase in PTH occurred by 15 mm, and the
PTH level gradually declined during the first hour but remained
greater than threefold the basal concentration for the duration
of the study. Thus, these studies performed in normal animals
suggest that maximum responses of PTH secretion occur with
minor decrements of plasma calcium, and despite the mainte-
nance of profound hypocalcemia, no further increment in PTH
secretion is observed. Our findings in dialysis patients with
parathyroid glandular hyperplasia are similar. Peak responses
in PTH levels are attained with only a minor decrease in plasma
calcium. No further increment of PTH concentration occurs
despite progressive hypocalcemia.
Three patients began the hemodialysis with a plasma calcium
level greater than 10 mgldl. In the three patients, marked
increases of both C-PTH and N-PTH were recorded with
plasma calcium levels greater than 9 mg/dl. In two additional
patients, both C-PTH and N-PTH markedly increased by the
first sampling although the plasma calcium level did not fall
below 9.0 mg/dl. Thus, the possibility exists that some of our
patients may have an altered set point. Such a finding would be
compatible with the in vitro studies by Brown et al [9], in which
parathyroid glands obtained from patients with secondary
hyperparathyroidism released PTH in cell culture at concentra-
tions of calcium greater than that observed with normal para-
thyroid gland cells.
It is possible that some of the increment of C-PTH and N-
PTH may be secondary to altered PTH metabolism or glandular
secretion of PTH fragments [13, 21—241. From our data, these
possibilities cannot be determined. Chronic renal failure has
been shown to alter the peripheral metabolism of intact PTH
[25]. In addition, changes in PTH may occur across the dialyz-
er. However, in six patients, both C-PTH and N-PTI-l concen-
trations were measured simultaneously in the arterial line and
the venous line, and no significant differences were found.
A significant correlation is observed between baseline C-PTH
and N-PTH concentration and the maximum concentration of
C-PTH and N-PTH achieved with a hypocalcemic stimulus
(Fig. 3). This may be due to the fact that the baseline PTH levels
may reflect parathyroid gland mass and that the larger glandular
mass produces the highest levels of PTH after maximum
stimulation. This interpretation is compatible with a model
proposed by Massry et al [7] and also by Parfitt [26] that the
increased mass of cells present in hyperplastic glands will
produce a large increase of PTH when stimulated by hypocalce-
mia. In support of our interpretation of Figure 3 and the
proposed models, McCarron et al [16] were able to demonstrate
in renal transplant recipients with residual hyperparathyroidism
that the increment in PTH levels produced by EDTA-stimulated
hypocalcemia correlated with parathyroid gland mass. Howev-
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Fig. 5. Comparison of the maximal change (max) in C-PTH produced by hypocalcemia and bone histology. A highly significant correlation is
observed when max C-PTH is compared to A osteoblastic osteoid (%); B active bone resorption (%), C osteoclasts/mm2, and U endosteal fibrosis
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er, from the present study it cannot be determined if the
increased PTH production is solely secondary to an increased
number of cells or in addition, individual cells are capable of
augmented PTH secretion.
In the present study, significant correlations were found with
basal N-PTH levels and osteoblastic osteoid, active resorption,
osteoclasts/mm2, and endosteal fibrosis. The correlations with
basal C-PTH levels were significant only for osteoblastic oste-
oid and active resorption. Several studies have demonstrated a
good correlation between C-PTH and bone histological catego-
ries [27, 281. Since C-PTH levels are dependent upon metabo-
lism of the intact hormone and possibly direct C-PTH fragment
secretion by the parathyroid gland, the assumption is that a
steady state is achieved and thus the basal C-PTH level reflects
hormonal production [29]. However, a major problem common-
ly observed is the existence of different antisera and standards
in various laboratories [30, 31]. Thus, comparison of PTH
values among different laboratories is difficult, and for any
assay sequential information must be available. For our C-PTH
and N-PTH assay, the basal N-PTH level appears to correlate
better with parameters of bone activity.
When the maximum change in C-PTH and N-PTH concentra-
tions, induced by hypocalcemia, were compared to bone histol-
ogy, a highly significant correlation was found with max C-
PTH. The correlations with zmax N-PTH were significant but
not as marked as those observed with max C-PTH. Similarly,
significant correlations were observed with maximum C-PTH
and N-PTH levels but again were not as marked as with max
C-PTH.
In general, most of the histologic correlations were more
significant with zmax PTH than basal PTH levels. This finding
suggests that the levels obtained after stimulation of the para-
thyroid gland may better reflect actual secretory activity than
basal levels. The correlations between a marker of biologic
activity, bone, and Amax PTH would seemingly represent the
effect of PTH secretion over an extended time period. This
suggests that there must have been periods when maximum or
near-maximum PTH secretion occurred prior to the study,
leading to this better correlation with max PTH than basal
PTH. In support of such a hypothesis, two recent studies have
reported that PTH secretion is pulsatile with rapid and some-
times wide fluctuations in blood concentrations of PTH [32, 33].
The correlation with bone histology was better with max C-
PTH than max N-PTH. A likely explanation is that with
marked production of PTH, N-PTH is rapidly metabolized,
especially during hypocalcemia, and hence our sampling was
not frequent enough to detect significant changes [34]. Con-
versely, C-PTH is an inactive fragment with a longer half-life;
circulating levels of this fragment are prolonged in renal failure
and thus may more accurately reflect PTH secretion [34].
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